As the race to generate compelling clinical data to prove the concept of antigen-specific
immunotherapies gains momentum, the 2nd Antigen-Specific Immune Tolerance Drug
Development Summit returns to Boston in 2019 to help large pharma, biotech and
academic researchers overcome the complexity of auto-immune mediated disorders, expand
opportunities through combination strategies and undertake a more precise and antigenspecific approach to novel drug development.